Role of new antibiotics in the treatment of acute bacterial skin and skin-structure infections.

Icon for Wolters Kluwer Related Articles

Role of new antibiotics in the treatment of acute bacterial skin and skin-structure infections.

Curr Opin Infect Dis. 2020 Apr;33(2):110-120

Authors: Bassetti M, Magnasco L, Del Puente F, Giacobbe DR

Abstract
PURPOSE OF REVIEW: To summarize the available efficacy and safety data of novel agents for treating acute bacterial skin and skin-structure infections (ABSSSI), focusing on those active against methicillin-resistant Staphylococcus aureus (MRSA).
RECENT FINDINGS: There are now several agents active against MRSA that are approved for the treatment of ABSSSI, including tedizolid, ceftaroline, dalbavancin, telavancin, oritavancin, delafloxacin, and omadacycline. In addition, iclaprim has completed phase-3 randomized clinical trials (RCTs).
SUMMARY: Considering the similar efficacy that arose from direct comparisons in phase-3 RCTs, in order to adopt the best approach for treating ABSSSI on patient-tailored basis, the different safety profiles and formulations of the different available agents should be balanced by taking into account the specific features of each treated patient in terms of baseline comorbidities, related risk of toxicity, need for hospitalization, possibility of early discharge, and expected adherence to outpatient oral therapy.

PMID: 32068643 [PubMed - in process]